**Simple answer: A complete cure for herpes (HSV-1 and HSV-2) is still not possible in 2026.** The World Health Organization's position is clear—herpes can be treated, but not cured. Medications can only reduce the duration and severity of symptoms, but cannot completely clear the latent virus hidden in nerve cells.
 |
| Latest Herpes Treatment 2026: New Medicines, Vaccines and Cure Research |
However, a truly historic breakthrough occurred in 2026: **Pritelivir (Hovilpri) was approved by the FDA**, the first herpes treatment drug with a new mechanism of action in nearly 30 years, for patients with weakened immune systems and resistance to conventional medications. Additionally, research into new-generation drugs and vaccines is constantly advancing.
## Pritelivir: A New Option for Immunocompromised Patients
On October 9, 2026, the US FDA approved Pritelivir (Hovilpri) tablets for the treatment of adult patients with weakened immune systems (such as those with organ transplants, HIV infection, or blood cancers) whose mucocutaneous HSV infections are resistant to or have not sufficiently responded to conventional medications such as acyclovir, valacyclovir, or famciclovir.
This drug belongs to the class of helicase-primase inhibitors (HPIs), which directly inhibit the helicase-primase complex required for viral DNA replication and do not require activation by viral thymidine kinase (TK). Therefore, it is also effective against TK-deficient, acyclovir-resistant virus strains. It is effective against both HSV-1 and HSV-2 and is taken orally—a 400 mg loading dose on the first day, followed by 100 mg daily.
Key data from the PRIOH-1 Phase 3 clinical trial (101 immunocompromised patients):
| Evaluation Index | Pritelivir Group | Other Treatment Groups |
| :--- | :--- | :--- |
| **Complete healing of all lesions by 28 days** | **63%** | 34% |
| **Complete healing of all lesions by 42 days** | **82%** | 42% |
| **Discontinuation due to side effects** | **2%** | 20% |
The most common side effect is headache. The biggest clinical advantage is that it can be taken orally at home, avoiding the need for hospitalization and IV drips (like foscarnet), which is crucial for patients with already weakened immune systems.
## Adibelivir (IM-250): Ability to Target Dormant Viruses
Adibelivir (IM-250) is another HPI drug. According to research published in *Antiviral Research* in 2026, it maintained activity against acyclovir-resistant viruses in testing on more than 50 clinical isolates and laboratory-adapted strains, and demonstrated synergistic effects in combination with acyclovir, penciclovir, and foscarnet. It is currently in clinical research.
## Vaccines: Still challenging, but data is accumulating
Moderna's Phase 1/2 clinical trial (NCT06033261) of its therapeutic genital herpes vaccine, mRNA-1608, published preliminary results in January 2026, including safety, immunogenicity, and clinical endpoint data. However, it has not yet been proven to effectively reduce disease incidence or transmission.
The NIH's 2026 review clearly stated that as of October 3, 2026, no vaccine has been approved by the FDA for the prevention or treatment of herpes infection. For an effective vaccine, neutralizing antibodies alone are not sufficient; both multifunctional antibodies and tissue-resident T cell immunity are required.
## Inactive Viruses: The Biggest Obstacle to a Real Cure
The NIH review specifically pointed out that even potent replication inhibitors like Pritelivir cannot clear chromatinized inactive virus in neurons. Inactivation-targeting strategies such as "shock-and-kill" (activating inactive virus and then killing it) or "block-and-lock" (permanently silencing inactive virus) are still largely in the preclinical stage and face challenges in delivery, safety, and long-term stability.
## Other Research Directions
Bispecific Antibodies: Research published in *Frontiers in Immunology* (May 2026) developed bispecific antibodies targeting both gB and gD simultaneously, which demonstrated significant synergistic effects in preventing cell-cell fusion, virus entry, and plaque formation, and exhibited activity against both HSV-1 and HSV-2.
**Conventional Therapy Combinations:** A study is registered in the WHO Clinical Trials Registry (ITMCTR2026000128) evaluating the combination of **Herpes Formula No. 2** and valacyclovir in patients with genital herpes outbreaks more than 6 times a year. The primary endpoint is recurrence rate. Patients are currently being recruited.
## Conclusion
**A complete cure for HSV-1 and HSV-2 is still not possible in 2026.** Pritelivir's approval is primarily for immunocompromised patients in whom conventional medications do not work, and it only controls symptoms, not clears dormant virus. Newer-generation HPI drugs like adalimumab and new targets like bispecific antibodies are expanding treatment options, but a true cure is still many years away.